Showing 1,721 - 1,740 results of 2,015 for search '(( significant small decrease ) OR ( significant ((larger decrease) OR (largest decrease)) ))', query time: 0.52s Refine Results
  1. 1721

    Forest plot for IL-6. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  2. 1722

    The incidence rate of adverse reactions. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  3. 1723

    The PRISMA study flowchart. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  4. 1724

    Forest plot for FEV1/FVC. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  5. 1725

    Forest plot for clinical efficacy. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  6. 1726

    Forest plot for FEV1. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  7. 1727

    The excluded and included studies were listed. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  8. 1728

    Forest plot for PaCO<sub>2</sub>. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  9. 1729

    Forest plot for PaO<sub>2</sub>. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  10. 1730

    Dual action of novel 5-nitroguaiacol-based hydrazones: Targeting aldolase-a and inducing apoptosis in lung cancer by Mürvet Tümenci (22474400)

    Published 2025
    “…Their <i>in vitro</i> cytotoxic effects were evaluated against human non-small cell lung cancer (A549) and normal bronchial epithelial cell lines (BEAS-2B) using the MTT assay. …”
  11. 1731

    Supplementary Material for: Interventions to prevent and manage infections in pregnancy by Yasin R. (19754247)

    Published 2025
    “…Changing a two-dose intermittent preventive treatment (IPTp) regimen to more frequent IPTp dosing decreased the risk of LBW) and significantly improved babies’ birthweight. …”
  12. 1732

    Supplementary file 1_Analysis of the diagnostic value of peripheral blood immune inflammatory indicators of female bladder pain syndrome.zip by Yinglei Wang (3844756)

    Published 2025
    “…Compared with the normal bladder capacity group, patients with small bladder capacity demonstrated significantly lower SII, PLR, PLT, with statistically significant differences (all P < 0.05). …”
  13. 1733

    The association of piR-651 and piR-823 on metastatic and invasive characteristics of triple negative breast cancer cells by Çağrı Öner (3152334)

    Published 2024
    “…The expressions of Ki-67, HIF-1α, MMP-2, and MMP-9 genes were measured at 48 h, when both cell lines exhibited the most significant effects of inhibition. The optimal time for proliferation of anti-piR-651 and anti-piR-823 transfected MDA-MB-231 cells was determined to be at 48 h, as indicated by decreased motility and invasion assay results (<i>p</i> < 0.001). …”
  14. 1734

    Table 1_Leaf senescence characteristics and economic benefits of rice under alternate wetting and drying irrigation and blended use of polymer-coated and common urea.docx by Dongliang Qi (3228141)

    Published 2024
    “…This suggested that AWD combined with N2 and N3 could delay the leaf senescence of rice, thus achieving a larger grain yield. Moreover, AWD significantly decreased water costs (irrigation amount) and labor costs (irrigation frequency), thus increasing total income. …”
  15. 1735

    Table 1_Ultrasonographic examination of the patellar ligament after capsular and fascial imbrication for the treatment of cranial cruciate ligament rupture in dogs.docx by Mario Candela Andrade (20932802)

    Published 2025
    “…Forty-six dogs with CCL ruptures treated at the Small Animal Clinic of Freie Universität Berlin between July 2013 and April 2015 were included. …”
  16. 1736

    Data Sheet 1_The effect of vagus nerve stimulation on heart rate and respiration rate and their impact on seizure susceptibility in anaesthetized rats under pentylenetetrazol.pdf by Javier Chávez Cerda (20913026)

    Published 2025
    “…Results indicate that the stimulation significantly decreased the heart rate below baseline levels for standard VNS (−120.0 ± 69.1 bpm) and breathing-synchronized VNS (−84.9 ± 61.0 bpm), overcoming the heart rate increasing effect of PTZ infusion observed in the sham VNS (+79.2 ± 35.5 bpm), and there was no recovery during OFF periods. …”
  17. 1737

    Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…Introduction<p>The incidence of chronic obstructive pulmonary disease (COPD) and non-alcoholic fatty liver disease (NAFLD) has increased significantly in past decades, posing a significant public health burden. …”
  18. 1738

    Table 1_Danggui Buxue Decoction attenuates 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone—induced lung cancer growth in A/J mice by suppressing HIF-1α/VEGF-mediated angiogenesis.do... by Wu Chen (569414)

    Published 2025
    “…By week 20, progressive multifocal opacities emerged alongside reduced pulmonary artery flow, impaired lung function, elevated TNF-α/VEGF, and decreased WBC, lymphocytes, and platelets. Compared to untreated controls, 10-week DBD treatment significantly suppressed lung tumor growth, reduced lesion microvessel density, downregulated HIF-1α and VEGF expression, and ameliorated hematological dysregulation.…”
  19. 1739

    Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…Introduction<p>The incidence of chronic obstructive pulmonary disease (COPD) and non-alcoholic fatty liver disease (NAFLD) has increased significantly in past decades, posing a significant public health burden. …”
  20. 1740

    Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…Introduction<p>The incidence of chronic obstructive pulmonary disease (COPD) and non-alcoholic fatty liver disease (NAFLD) has increased significantly in past decades, posing a significant public health burden. …”